References analysis of the Wikipedia article "Бета-блокатор" in the Ukrainian version

nih.gov

ncbi.nlm.nih.gov

Frishman WH1, Saunders E. β-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011 Sep;13(9):649-53 [Архівовано 3 січня 2015 у Wayback Machine.]

Thomopoulos C1, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — Overview and meta-analyses. J Hypertens. 2015 Feb;33(2):195-211 [Архівовано 3 січня 2015 у Wayback Machine.]

Baker JG1, Hill SJ, Summers RJ. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. 2011 Apr;32(4):227-34 [Архівовано 3 січня 2015 у Wayback Machine.]

Elgendy IY, Mahmoud A, Conti CR. Beta-Blockers in the Management of Coronary Artery Disease: Are we on the Verge of a New Paradigm Shift? Recent Pat Cardiovasc Drug Discov. 2014 Sep 1. [[https://web.archive.org/web/20150103220231/http://www.ncbi.nlm.nih.gov/pubmed/25174339 Архівовано 3 січня 2015 у Wayback Machine.] [Epub ahead of print]]

Berg T, Piercey BW, Jensen J. Role of beta1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats. Hypertension. 2010 May;55(5):1224-30 [Архівовано 3 січня 2015 у Wayback Machine.]

Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs. 2007;67(8):1097-107 [Архівовано 14 квітня 2016 у Wayback Machine.]

Karter Y. Nebivolol: more than a highly selective Beta blocker. Recent Pat Cardiovasc Drug Discov. 2007 Jun;2(2):152-5 [Архівовано 27 грудня 2015 у Wayback Machine.]

Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol. 1990 Sep 25;66(9):21C-23C. [Архівовано 15 грудня 2014 у Wayback Machine.]

Heusser K, Schobel HP, Adamidis A, Fischer T, Frank H. Cardiovascular effects of beta-blockers with and without intrinsic sympathomimetic activity. A comparison between celiprolol and metoprolol. Kidney Blood Press Res. 2002;25(1):34-41

Brixius K, Bundkirchen A, Bölck B, Mehlhorn U, Schwinger RH. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in humanmyocardium. Br J Pharmacol. 2001 Aug;133(8):1330-8 [Архівовано 8 грудня 2010 у Wayback Machine.]

Jillian G. Baker, Stephen J. Hill,1 and Roger J. Summers. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. Apr 2011; 32(4-2): 227—234

Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003 Dec;100(3):215-34 [Архівовано 4 січня 2015 у Wayback Machine.]

Reddy S et al. Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy. [[https://web.archive.org/web/20150104161757/http://www.ncbi.nlm.nih.gov/pubmed/25406899 Архівовано 4 січня 2015 у Wayback Machine.] Pediatr Res. 2014 Nov 19. doi: 10.1038/pr.2014.183. [Epub ahead of print]]

Fiuzat M et al. Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. Eur J Heart Fail. 2013 Mar;15(3):258-66 [Архівовано 4 січня 2015 у Wayback Machine.]

Abbas M et al. Assessment of sex differences in Pharmacokinetics of carvedilol in human. Pak J Pharm Sci. 2014 Sep;27(5):1265-9 [Архівовано 4 січня 2015 у Wayback Machine.]

Aleong RG et al. Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug;1(4):338-44 [Архівовано 4 січня 2015 у Wayback Machine.]

Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27 [Архівовано 4 січня 2015 у Wayback Machine.]

Bangalore S et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med. 2014 Oct;127(10):939-53 [Архівовано 4 січня 2015 у Wayback Machine.]

Raposeiras-Roubín S et al. Prognostic Benefit of Beta-blockers After Acute Coronary Syndrome With Preserved Systolic Function. Still Relevant Today? Rev Esp Cardiol (Engl Ed). 2014 Dec 12. pii: S1885-5857(14)00403-4 [Архівовано 4 січня 2015 у Wayback Machine.]

Bonten TN et al. Effect of β-blockers on platelet aggregation: a systematic review and meta-analysis. Br J Clin Pharmacol. 2014 Nov;78(5):940-9 [Архівовано 4 січня 2015 у Wayback Machine.]

Morales DR et al. Adverse respiratory effect of acute β-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest. 2014 Apr;145(4):779-86 [Архівовано 4 січня 2015 у Wayback Machine.]

Du Q et al. Beta-Blockers Reduced the Risk of Mortality and Exacerbation in Patients with COPD: A Meta-Analysis of Observational Studies. PLoS One. 2014 Nov 26;9(11): e113048 [Архівовано 4 січня 2015 у Wayback Machine.]

Corino VD et al. Non-invasive evaluation of the effect of metoprolol on the atrioventricular node during permanent atrial fibrillation. Europace. 2014 Nov;16 Suppl 4:iv129-iv134 [Архівовано 4 січня 2015 у Wayback Machine.]

Rose-Jones LJ, Bode WD, Gehi AK. Current approaches to antiarrhythmic therapy in heart failure. Heart Fail Clin. 2014 Oct;10(4):635-52 [Архівовано 4 січня 2015 у Wayback Machine.]

Frishman WH, Aronow WS. Pharmacology of antiarrhythmic drugs in elderly patients. Clin Geriatr Med. 2012 Nov;28(4):575-615 [Архівовано 4 січня 2015 у Wayback Machine.]

Piccini JP et al. Comparison of safety of sotalol versus amiodarone in patients with atrial fibrillation and coronary artery disease. Am J Cardiol. 2014 Sep 1;114(5):716-22 [Архівовано 4 січня 2015 у Wayback Machine.]

Al-Gobari M, El Khatib C, Pillon F, Gueyffier F. et al. β-Blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2013 Jul 13;13:52 [Архівовано 5 жовтня 2015 у Wayback Machine.]

Spoladore R et al. Beneficial effects of beta-blockers on left ventricular function and cellular energy reserve in patients with heart failure. Fundam Clin Pharmacol. 2013 Aug;27(4):455-64 [Архівовано 22 березня 2012 у Wayback Machine.]

Packer M et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194-9 [Архівовано 12 травня 2015 у Wayback Machine.]

Capomolla S et al. Beta-blockade therapy in chronic heart failure: diastolic function and mitral regurgitation improvement by carvedilol. Am Heart J. 2000 Apr;139(4):596-608

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13 [Архівовано 29 грудня 2014 у Wayback Machine.]

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001-7 [Архівовано 8 листопада 2014 у Wayback Machine.]

Flather MD et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215-25 [Архівовано 23 квітня 2014 у Wayback Machine.]

de Peuter OR et al. Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. Eur J Heart Fail. 2011 Feb;13(2):220-6

Ripley TL, Saseen JJ et al. β-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014 Jun;48(6):723-33 [Архівовано 8 січня 2015 у Wayback Machine.]

Wiysonge CS et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007 Jan 24;(1): CD002003 [Архівовано 8 січня 2015 у Wayback Machine.]

Ladage D, Schwinger RH, Brixius K et al. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. Cardiovasc Ther. 2013 Apr;31(2):76-83 [Архівовано 8 січня 2015 у Wayback Machine.]

Elliott WJ, Meyer PM et al. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007 Jan 20;369(9557):201-7 [Архівовано 8 січня 2015 у Wayback Machine.]

Mayor S. NICE removes beta blockers as first line treatment for hypertension. BMJ. 2006 Jul 1;333(7557):8 [Архівовано 31 березня 2022 у Wayback Machine.]

Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005 Oct 29-Nov 4;366(9496):1545-53 [Архівовано 9 грудня 2014 у Wayback Machine.]

Webb AJ, Fischer U, Rothwell PM. Effects of β-blocker selectivity on blood pressure variability and stroke: a systematic review. Neurology. 2011 Aug 23;77(8):731-7 [Архівовано 8 січня 2015 у Wayback Machine.]

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — Overview and meta-analyses. J Hypertens. 2015 Feb;33(2):195-211 [Архівовано 3 січня 2015 у Wayback Machine.]

Hernández-Gea V et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012 Mar;107(3):418-27 [Архівовано 10 січня 2015 у Wayback Machine.]

Reiberger T et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013 May;58(5):911-21 [Архівовано 10 січня 2015 у Wayback Machine.]

Sinagra E et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014 Mar;39(6):557-68 [Архівовано 10 січня 2015 у Wayback Machine.]

Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liver Int. 2014 May;34(5):655-67 [Архівовано 10 січня 2015 у Wayback Machine.]

Thiele M et al. Can non-selective beta-blockers prevent hepatocellular carcinoma in patients with cirrhosis? Med Hypotheses. 2013 Nov;81(5):871-4 [Архівовано 10 січня 2015 у Wayback Machine.]

Abu-Zeitone A et al. Efficacy of different beta-blockers in the treatment of long QT syndrome. J Am Coll Cardiol. 2014 Sep 30;64(13):1352-8 [Архівовано 10 січня 2015 у Wayback Machine.]

Bennett MT et al. Effect of beta-blockers on QT dynamics in the long QT syndrome: measuring the benefit. Europace. 2014 Dec;16(12):1847-51 [Архівовано 10 січня 2015 у Wayback Machine.]

Gelmetti C, Cavalli R. Beta-blockers for hemangiomas. [[https://web.archive.org/web/20150110101448/http://www.ncbi.nlm.nih.gov/pubmed/25366892 Архівовано 10 січня 2015 у Wayback Machine.] G Ital Dermatol Venereol. 2014 Nov 4. [Epub ahead of print]]

Toppen W et al. Do preoperative β-blockers improve postoperative outcomes in patients undergoing cardiac surgery? Challenging societal guidelines. Am Surg. 2014 Oct;80(10):1018-21 [Архівовано 10 січня 2015 у Wayback Machine.]

Blessberger H et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev. 2014 Sep 18;9:CD004476 [Архівовано 10 січня 2015 у Wayback Machine.]

P. Turner. Therapeutic uses of beta-adrenoceptor blocking drugs in the central nervous system in man. Postgrad Med J. Jan 1989; 65(759): 1–6

Lindgren ME et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013 Aug;22(8):1889-94 [Архівовано 10 січня 2015 у Wayback Machine.]

Abu Ruz ME, Lennie TA, Moser DK. Effects of β-blockers and anxiety on complication rates after acute myocardial infarction. Am J Crit Care. 2011 Jan;20(1):67-73 [Архівовано 10 січня 2015 у Wayback Machine.]

Hoogwegt MT et al. Beta-blocker therapy is not associated with symptoms of depression and anxiety in patients receiving an implantable cardioverter-defibrillator. Europace. 2012 Jan;14(1):74-80 [Архівовано 10 січня 2015 у Wayback Machine.]

web.archive.org

Frishman WH1, Saunders E. β-Adrenergic blockers. J Clin Hypertens (Greenwich). 2011 Sep;13(9):649-53 [Архівовано 3 січня 2015 у Wayback Machine.]

López-Sendón J et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004 Aug;25(15):1341-62 [Архівовано 23 грудня 2015 у Wayback Machine.]

Karter Y. Nebivolol: more than a highly selective Beta blocker. Recent Pat Cardiovasc Drug Discov. 2007 Jun;2(2):152-5 [Архівовано 27 грудня 2015 у Wayback Machine.]

Jaillon P. Relevance of intrinsic sympathomimetic activity for beta blockers. Am J Cardiol. 1990 Sep 25;66(9):21C-23C. [Архівовано 15 грудня 2014 у Wayback Machine.]

Candy Lashkari. Sir James Black inventor of beta-blockers passes away. March 23, 2010 news-medical.net [Архівовано 26 березня 2010 у Wayback Machine.]

Toda N. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. Pharmacol Ther. 2003 Dec;100(3):215-34 [Архівовано 4 січня 2015 у Wayback Machine.]

Abbas M et al. Assessment of sex differences in Pharmacokinetics of carvedilol in human. Pak J Pharm Sci. 2014 Sep;27(5):1265-9 [Архівовано 4 січня 2015 у Wayback Machine.]

Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27 [Архівовано 4 січня 2015 у Wayback Machine.]

Frishman WH, Aronow WS. Pharmacology of antiarrhythmic drugs in elderly patients. Clin Geriatr Med. 2012 Nov;28(4):575-615 [Архівовано 4 січня 2015 у Wayback Machine.]

The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9-13 [Архівовано 29 грудня 2014 у Wayback Machine.]

Wiysonge CS et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007 Jan 24;(1): CD002003 [Архівовано 8 січня 2015 у Wayback Machine.]

Mayor S. NICE removes beta blockers as first line treatment for hypertension. BMJ. 2006 Jul 1;333(7557):8 [Архівовано 31 березня 2022 у Wayback Machine.]

Tripathi D, Hayes PC. Beta-blockers in portal hypertension: new developments and controversies. Liver Int. 2014 May;34(5):655-67 [Архівовано 10 січня 2015 у Wayback Machine.]

Better Playing Through Chemistry [Архівовано 29 серпня 2011 у Wayback Machine.] by Blair Tindall, New York Times, October 17, 2004. (Discusses the use of beta blockers among professional musicians)

Musicians using beta blockers [Архівовано 4 вересня 2009 у Wayback Machine.] by Blair Tindall. Condensed version of above article.

Бета-блокатор (Ukrainian Wikipedia)

news-medical.net

nih.gov

ncbi.nlm.nih.gov

nytimes.com

oxfordjournals.org

eurheartj.oxfordjournals.org

sfgate.com

web.archive.org